查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1536675

糖尿病神經病變治療市場，按疾病類型、藥物類別、配銷通路、國家和地區 - 2024-2032 年行業分析、市場規模、市場佔有率和預測

Diabetic Neuropathy Treatment Market, By Disease Type, By Drug Class, By Distribution Channel, By Country, and By Region - Industry Analysis, Market Size, Market Share & Forecast from 2024-2032
出版日期: | 出版商: AnalystView Market Insights | 英文 288 Pages | 商品交期: 2-3個工作天內

價格

報告要點

2023年糖尿病神經病變治療市場規模為43.9032億美元，2024年至2032年複合年成長率為8.10%。

糖尿病神經病變治療市場-市場動態

糖尿病治療診斷技術的改進和創新療法預計將推動市場需求

全球糖尿病（尤其是第 2 型糖尿病）發生率的不斷上升是市場成長的關鍵驅動力。隨著糖尿病患者數量的增加，對糖尿病神經病變等併發症的有效治療的需求也在增加。診斷技術的進步和認知的提高可以更早、更準確地診斷糖尿病神經病變。早期診斷通常會帶來更好的管理和治療結果，從而增加對治療的需求。新興市場更高的醫療支出和改善的醫療基礎設施有助於糖尿病神經病變治療市場的成長。

增加對研究和新療法的投資，包括新型藥物、生物製劑和醫療設備，有助於市場成長。藥物輸送系統和治療方法的創新增強了治療選擇。政府對糖尿病研究和治療的舉措和資助，以及糖尿病神經病變治療的優惠報銷政策，支持了市場成長。新藥物和療法引入市場，包括針對特定神經性疼痛途徑或提供更好療效和安全性的藥物和療法，推動了市場成長。

糖尿病神經病變治療市場 - 關鍵見解

根據我們的研究分析師分享的分析，預計全球市場在預測期內（2024-2032 年）每年將以 8.10% 左右的複合年成長率成長

根據疾病類型細分，預計周邊神經病變細分市場將在 2023 年顯示最大的市場佔有率，因為它是最常見的糖尿病神經病變形式之一。

根據藥物類別細分，非類固醇抗發炎藥物 (NSAID) 因其市場可承受性而成為 2023 年領先的藥物類別。

根據配銷通路細分，由於醫院藥房的用藥量較高，醫院藥房細分市場將成為 2023 年的主要配銷通路。

從地區來看，由於擁有發達的糖尿病治療醫療基礎設施，北美將成為 2023 年的主要收入來源。

糖尿病神經病變治療市場-細分分析：

全球糖尿病神經病變治療市場根據疾病類型、藥物類別、配銷通路和地區進行細分。

根據疾病類型，市場分為四類：周邊神經病變、自主神經病變、近端神經病變和局部神經病變。周邊神經病變領域主導市場。老年人中糖尿病的高盛行率正在推動細分市場的需求。

依藥物類別，市場分為四類：辣椒素、鴉片類藥物、非類固醇抗發炎藥（NSAID）等。非類固醇抗發炎藥（NSAID）預計將佔據最大的市場佔有率。據估計，鴉片類藥物市場在預測期內將以最快的速度成長。鴉片類藥物是強效鎮痛藥，可以更有效地緩解疼痛。

根據分銷管道，市場分為三類：醫院藥房、零售藥房和其他。醫院藥房領域在市場中佔據主導地位，預計在預測期內將保持其較高的主導地位。醫院藥房擁有一個用於管理藥物的整合系統，這使得處理更容易，因此得到了更多的採用。

糖尿病神經病變治療市場 - 地理洞察

從地理來看，該市場廣泛分佈於北美、拉丁美洲、歐洲、亞太、中東和非洲等地區。由於糖尿病盛行率高和醫療基礎設施先進，北美（主要是美國）在全球糖尿病神經病變治療市場中佔有重要佔有率。由於糖尿病發病率上升和醫療基礎設施改善，包括中國和印度等國家在內的亞太地區糖尿病神經病變治療市場正在快速成長。

糖尿病神經病變治療市場-競爭格局：

糖尿病神經病變治療市場競爭適中，有許多公司參與開發和提供糖尿病治療解決方案。市場參與者正在開發與糖尿病神經病變相關的特定疼痛途徑的新藥，包括新配方和標靶治療。由於糖尿病盛行率上升和醫療基礎設施不斷擴大，公司越來越關注亞太和拉丁美洲等新興市場。

最新進展：

2023 年 12 月，Vertex Pharmaceuticals 獲得 FDA 批准基於 CRISPR 的基因編輯療法，這是一項專注於開發非鴉片類疼痛管理藥物的策略性舉措。

2023 年 7 月，印度製藥公司 Asprius Lifesciences 推出了一種針對糖尿病神經病變（一種導致神經損傷的疾病）的治療方法。

2022 年，Axovant 基因療法正在探索先進的治療方法，包括神經系統疾病的基因和細胞療法。

目錄

第1章：糖尿病神經病變治療市場概述

  • 研究範圍
  • 市場預估年份

第 2 章：執行摘要

  • 市場片段
    • 按疾病類型分類的糖尿病神經病變治療市場片段
    • 按藥物類別分類的糖尿病神經病變治療市場片段
    • 按配銷通路分類的糖尿病神經病變治療市場片段
    • 按國家/地區分類的糖尿病神經病變治療市場片段
    • 按地區分類的糖尿病神經病變治療市場片段
  • 競爭洞察

第 3 章：糖尿病神經病變治療主要市場趨勢

  • 糖尿病神經病變治療市場促進因素
    • 市場促進因素的影響分析
  • 糖尿病神經病變治療市場限制
    • 市場限制影響分析
  • 糖尿病神經病變治療市場機會
  • 糖尿病神經病變治療市場未來趨勢

第 4 章：糖尿病神經病變治療產業研究

  • PEST分析
  • 波特五力分析
  • 成長前景圖
  • 規範架構分析

第 5 章：糖尿病神經病變治療市場：COVID-19 影響分析

  • COVID-19 之前的影響分析
  • COVID-19 後影響分析
    • 表現最佳的市場區隔
    • 邊際成長市場區隔
    • 最寬鬆的市場區隔
    • 邊際損失市場區隔

第 6 章：糖尿病神經病變治療市場格局

  • 2023 年糖尿病神經病變治療市佔率分析
  • 按主要製造商分類的故障數據
    • 既有參與者分析
    • 新興參與者分析

第 7 章：糖尿病神經病變治療市場 - 依疾病類型

  • 概述
    • 按疾病類型分類的細分市場佔有率分析
    • 周邊神經病變
    • 自主神經病變
    • 近端神經病變
    • 局部神經病變

第 8 章：糖尿病神經病變治療市場 - 依藥物類別

  • 概述
    • 按藥物類別分類的細分市場佔有率分析
    • 辣椒素
    • 鴉片類藥物
    • 非類固醇類抗發炎藥 (NSAID)
    • 其他

第 9 章：糖尿病神經病變治療市場 - 按配銷通路

  • 概述
    • 按配銷通路分類的細分市場佔有率分析
    • 醫院藥房
    • 零售藥局
    • 其他

第 10 章：糖尿病神經病變治療市場 - 按地理位置

  • 介紹
    • 按地理位置分類的細分市場佔有率分析
  • 北美洲
    • 概述
    • 北美糖尿病神經病變治療主要製造商
    • 北美市場規模和預測（按國家）
    • 北美市場規模和預測（按疾病類型）
    • 北美市場規模和預測（按藥物類別）
    • 北美市場規模和預測（按配銷通路）
    • 美國
    • 加拿大
  • 歐洲
    • 概述
    • 歐洲糖尿病神經病變治療主要製造商
    • 歐洲市場規模和預測（按國家）
    • 歐洲市場規模與預測（按疾病類型）
    • 歐洲市場規模和預測（按藥物類別）
    • 歐洲市場規模和預測（按配銷通路）
    • 德國
    • 義大利
    • 英國
    • 法國
    • 俄羅斯
    • 荷蘭
    • 瑞典
    • 波蘭
    • 歐洲其他地區
  • 亞太地區 (APAC)
    • 概述
    • 亞太地區糖尿病神經病變治療主要製造商
    • 亞太地區市場規模與預測（按國家）
    • 亞太地區市場規模與預測（按疾病類型）
    • 亞太地區市場規模和預測（按藥物類別）
    • 亞太地區市場規模和預測（按配銷通路）
    • 印度
    • 中國
    • 日本
    • 韓國
    • 澳洲
    • 泰國
    • 印尼
    • 菲律賓
    • 亞太地區其他地區
  • 拉丁美洲
    • 概述
    • 拉丁美洲糖尿病神經病變治療主要製造商
    • 拉丁美洲市場規模與預測（按國家）
    • 拉丁美洲市場規模與預測（按疾病類型）
    • 拉丁美洲市場規模與預測（按藥物類別）
    • 拉丁美洲市場規模和預測（按配銷通路）
    • 巴西
    • 墨西哥
    • 阿根廷
    • 哥倫比亞
    • 拉丁美洲其他地區
  • 中東和非洲
    • 概述
    • 中東和非洲糖尿病神經病變治療主要製造商
    • 中東和非洲市場規模及預測（按國家）
    • 中東和非洲市場規模及預測（按疾病類型）
    • 中東和非洲市場規模及預測（按藥物類別）
    • 中東和非洲市場規模及預測（按配銷通路）
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 以色列
    • 土耳其
    • 阿爾及利亞
    • 埃及
    • MEA 的其餘部分

第 11 章：主要供應商分析 - 糖尿病神經病變治療產業

  • 競爭儀表板
  • 公司簡介
    • Pfizer Inc.
    • Eli Lilly and Company
    • Astellas Pharma Inc.
    • GlaxoSmithKline plc.
    • Boehringer Ingelheim
    • NeuroMetrix Inc.
    • Axovant Gene Therapies Ltd.
    • Eton Pharmaceuticals
    • Alnylam Pharmaceuticals
    • Novartis International AG
    • Sanofi
    • Johnson & Johnson
    • Amgen Inc.
    • AbbVie Inc.
    • Merck & Co.
    • Vertex Pharmaceuticals
    • Others

第 12 章：360 度分析師視角

第 13 章：附錄

  • 研究方法
  • 參考
  • 縮寫
  • 免責聲明
  • 聯絡我們
Product Code: ANV3524

REPORT HIGHLIGHT

Diabetic Neuropathy Treatment Market size was valued at USD 4,390.32 Million in 2023, expanding at a CAGR of 8.10% from 2024 to 2032.

Diabetic neuropathy is a type of nerve damage that can occur in people with diabetes, usually because of prolonged high blood sugar levels. Treatment typically focuses on managing symptoms and preventing further nerve damage.

Diabetic Neuropathy Treatment Market- Market Dynamics

Improved diagnostic techniques in diabetes treatment and innovative therapies are expected to propel market demand

The growing incidence of diabetes, particularly type 2 diabetes, worldwide is a key driver of the market growth. As the number of diabetes patients increases, so does the demand for effective treatments for complications such as diabetic neuropathy. Advances in diagnostic technologies and increased awareness lead to earlier and more accurate diagnosis of diabetic neuropathy. Early diagnosis often leads to better management and treatment outcomes, increasing the demand for therapies. Higher healthcare spending and improved healthcare infrastructure in emerging markets contribute to the growth of the diabetic neuropathy treatment market.

Increasing investment into research & new treatments and therapies, including novel pharmaceuticals, biologics, and medical devices, contributes to market growth. Innovations in drug delivery systems and therapeutic approaches enhance treatment options. Government initiatives and funding for diabetes research and treatment, as well as favorable reimbursement policies for diabetic neuropathy therapies, support market growth. The introduction of new drugs and therapies into the market, including those targeting specific neuropathic pain pathways or providing better efficacy and safety profiles, drives market growth.

Diabetic Neuropathy Treatment Market- Key Insights

As per the analysis shared by our research analyst, the global market is estimated to grow annually at a CAGR of around 8.10% over the forecast period (2024-2032)

Based on Disease Type segmentation, the peripheral neuropathy segment was predicted to show maximum market share in the year 2023, as it is one of the most common forms of diabetic neuropathy.

Based on Drug Class segmentation, the non-steroidal anti-inflammatory drugs (NSAIDs) segment was the leading Drug Class in 2023, due to its affordability in the market.

Based on Distribution Channel segmentation, the hospital pharmacies segment was the leading Distribution Channel in 2023, owing to high medication at hospital pharmacies.

On the basis of region, North America was the leading revenue generator in 2023, owing to the presence of developed healthcare infrastructure for diabetic treatment.

Diabetic Neuropathy Treatment Market- Segmentation Analysis:

The Global Diabetic Neuropathy Treatment Market is segmented on the basis of Disease Type, Drug Class, Distribution Channel, and Region.

The market is divided into four categories based on Disease Type: peripheral neuropathy, autonomic neuropathy, proximal neuropathy, and focal neuropathy. The peripheral neuropathy segment dominates the market. The high prevalence of diabetes among old adults is boosting segment demand.

The market is divided into four categories based on Drug Class: capsaicin, opioid, Non-Steroidal Anti-inflammatory Drugs (NSAIDs), and others. The Non-Steroidal Anti-inflammatory Drugs (NSAIDs) segment is projected to hold the largest share of the market. The opioid segment is estimated to grow at the fastest rate over the forecast period. Opioids are potent analgesics that can provide more effective pain relief.

The market is divided into three categories based on Distribution channels: hospital pharmacies, retail pharmacies, and others. The hospital pharmacies segment dominates the market and is expected to maintain its high dominance during the forecast period. Hospital pharmacies have an integrated system for managing medications, which makes it easier to process and hence have greater adoption.

Diabetic Neuropathy Treatment Market- Geographical Insights

Geographically, this market is widespread in the regions of North America, Latin America, Europe, Asia Pacific, and the Middle East and Africa. North America, predominantly the United States, holds a significant share of the global diabetic neuropathy treatment market due to a high prevalence of diabetes and advanced healthcare infrastructure. The Asia-Pacific region, including countries like China and India, is experiencing rapid growth in the diabetic neuropathy treatment market due to rising diabetes rates and improving healthcare infrastructure.

Diabetic Neuropathy Treatment Market- Competitive Landscape:

The diabetic neuropathy treatment market is moderately competitive, with numerous companies involved in developing and offering diabetic treatment solutions. Market players are working on novel drugs targeting specific pain pathways associated with diabetic neuropathy including new formulations and targeted therapies. Companies are increasingly focusing on emerging markets such as Asia-Pacific and Latin America due to the rising prevalence of diabetes and expanding healthcare infrastructure.

Recent Developments:

In December 2023, Vertex Pharmaceuticals got FDA approval for CRISPR-based gene editing therapy, a strategic move which focuses on the development of non-opioid pain management drugs.

In July 2023, Asprius Lifesciences, an Indian pharmaceutical company, has launched a treatment for Diabetic Neuropathy, a condition causing nerve damage.

In 2022, Axovant Gene Therapies is exploring advanced treatments including gene and cell therapies for neurological conditions.

SCOPE OF THE REPORT

The scope of this report covers the market by its major segments, which include as follows:

GLOBAL DIABETIC NEUROPATHY TREATMENT MARKET KEY PLAYERS

  • Pfizer Inc.
  • Eli Lilly and Company
  • Astellas Pharma Inc.
  • GlaxoSmithKline plc.
  • Boehringer Ingelheim
  • NeuroMetrix Inc.
  • Axovant Gene Therapies Ltd.
  • Eton Pharmaceuticals
  • Alnylam Pharmaceuticals
  • Novartis International AG
  • Sanofi
  • Johnson & Johnson
  • Amgen Inc.
  • AbbVie Inc.
  • Merck & Co.
  • Vertex Pharmaceuticals
  • Others

GLOBAL DIABETIC NEUROPATHY TREATMENT MARKET, BY DISEASE TYPE- MARKET ANALYSIS, 2019-2032

  • Peripheral neuropathy
  • Autonomic neuropathy
  • Proximal neuropathy
  • Focal neuropathy

GLOBAL DIABETIC NEUROPATHY TREATMENT MARKET, BY DRUG CLASS- MARKET ANALYSIS, 2019-2032

  • Capsaicin
  • Opioid
  • Non-Steroidal Anti-inflammatory Drugs (NSAIDs)
  • Others

GLOBAL DIABETIC NEUROPATHY TREATMENT MARKET, BY DISTRIBUTION CHANNEL- MARKET ANALYSIS, 2019-2032

  • Hospital Pharmacies
  • Retail Pharmacies
  • Others

GLOBAL DIABETIC NEUROPATHY TREATMENT MARKET, BY REGION- MARKET ANALYSIS, 2019-2032

  • North America
  • The U.S.
  • Canada
  • Europe
  • Germany
  • France
  • Italy
  • Spain
  • United Kingdom
  • Russia
  • Netherlands
  • Sweden
  • Poland
  • Rest of Europe
  • Asia Pacific
  • India
  • China
  • South Korea
  • Japan
  • Australia
  • Thailand
  • Indonesia
  • Philippines
  • Rest of APAC
  • Latin America
  • Brazil
  • Mexico
  • Argentina
  • Colombia
  • Rest of LATAM
  • The Middle East and Africa
  • Saudi Arabia
  • United Arab Emirates
  • Israel
  • Turkey
  • Algeria
  • Egypt
  • Rest of MEA

Table of Contents

1. Diabetic Neuropathy Treatment Market Overview

  • 1.1. Study Scope
  • 1.2. Market Estimation Years

2. Executive Summary

  • 2.1. Market Snippet
    • 2.1.1. Diabetic Neuropathy Treatment Market Snippet by Disease Type
    • 2.1.2. Diabetic Neuropathy Treatment Market Snippet by Drug Class
    • 2.1.3. Diabetic Neuropathy Treatment Market Snippet by Distribution Channel
    • 2.1.4. Diabetic Neuropathy Treatment Market Snippet by Country
    • 2.1.5. Diabetic Neuropathy Treatment Market Snippet by Region
  • 2.2. Competitive Insights

3. Diabetic Neuropathy Treatment Key Market Trends

  • 3.1. Diabetic Neuropathy Treatment Market Drivers
    • 3.1.1. Impact Analysis of Market Drivers
  • 3.2. Diabetic Neuropathy Treatment Market Restraints
    • 3.2.1. Impact Analysis of Market Restraints
  • 3.3. Diabetic Neuropathy Treatment Market Opportunities
  • 3.4. Diabetic Neuropathy Treatment Market Future Trends

4. Diabetic Neuropathy Treatment Industry Study

  • 4.1. PEST Analysis
  • 4.2. Porter's Five Forces Analysis
  • 4.3. Growth Prospect Mapping
  • 4.4. Regulatory Framework Analysis

5. Diabetic Neuropathy Treatment Market: COVID-19 Impact Analysis

  • 5.1. Pre-COVID-19 Impact Analysis
  • 5.2. Post-COVID-19 Impact Analysis
    • 5.2.1. Top Performing Segments
    • 5.2.2. Marginal Growth Segments
    • 5.2.3. Top Looser Segments
    • 5.2.4. Marginal Loss Segments

6. Diabetic Neuropathy Treatment Market Landscape

  • 6.1. Diabetic Neuropathy Treatment Market Share Analysis, 2023
  • 6.2. Breakdown Data, by Key Manufacturer
    • 6.2.1. Established Players' Analysis
    • 6.2.2. Emerging Players' Analysis

7. Diabetic Neuropathy Treatment Market - By Disease Type

  • 7.1. Overview
    • 7.1.1. Segment Share Analysis, By Disease Type, 2024 & 2032 (%)
    • 7.1.2. Peripheral neuropathy
    • 7.1.3. Autonomic neuropathy
    • 7.1.4. Proximal neuropathy
    • 7.1.5. Focal neuropathy

8. Diabetic Neuropathy Treatment Market - By Drug Class

  • 8.1. Overview
    • 8.1.1. Segment Share Analysis, By Drug Class, 2024 & 2032 (%)
    • 8.1.2. Capsaicin
    • 8.1.3. Opioid
    • 8.1.4. Non-Steroidal Anti-inflammatory Drugs (NSAIDs)
    • 8.1.5. Others

9. Diabetic Neuropathy Treatment Market - By Distribution Channel

  • 9.1. Overview
    • 9.1.1. Segment Share Analysis, By Distribution Channel, 2024 & 2032 (%)
    • 9.1.2. Hospital Pharmacies
    • 9.1.3. Retail Pharmacies
    • 9.1.4. Others

10. Diabetic Neuropathy Treatment Market- By Geography

  • 10.1. Introduction
    • 10.1.1. Segment Share Analysis, By Geography, 2024 & 2032 (%)
  • 10.2. North America
    • 10.2.1. Overview
    • 10.2.2. Diabetic Neuropathy Treatment Key Manufacturers in North America
    • 10.2.3. North America Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 10.2.4. North America Market Size and Forecast, By Disease Type, 2019 - 2032 (US$ Million)
    • 10.2.5. North America Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
    • 10.2.6. North America Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 10.2.7. U.S.
      • 10.2.7.1. Overview
      • 10.2.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.2.7.3. U.S. Market Size and Forecast, By Disease Type, 2019 - 2032 (US$ Million)
      • 10.2.7.4. U.S. Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 10.2.7.5. U.S. Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 10.2.8. Canada
      • 10.2.8.1. Overview
      • 10.2.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.2.8.3. Canada Market Size and Forecast, By Disease Type, 2019 - 2032 (US$ Million)
      • 10.2.8.4. Canada Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 10.2.8.5. Canada Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
  • 10.3. Europe
    • 10.3.1. Overview
    • 10.3.2. Diabetic Neuropathy Treatment Key Manufacturers in Europe
    • 10.3.3. Europe Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 10.3.4. Europe Market Size and Forecast, By Disease Type, 2019 - 2032 (US$ Million)
    • 10.3.5. Europe Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
    • 10.3.6. Europe Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 10.3.7. Germany
      • 10.3.7.1. Overview
      • 10.3.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.3.7.3. Germany Market Size and Forecast, By Disease Type, 2019 - 2032 (US$ Million)
      • 10.3.7.4. Germany Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 10.3.7.5. Germany Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 10.3.8. Italy
      • 10.3.8.1. Overview
      • 10.3.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.3.8.3. Italy Market Size and Forecast, By Disease Type, 2019 - 2032 (US$ Million)
      • 10.3.8.4. Italy Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 10.3.8.5. Italy Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 10.3.9. United Kingdom
      • 10.3.9.1. Overview
      • 10.3.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.3.9.3. United Kingdom Market Size and Forecast, By Disease Type, 2019 - 2032 (US$ Million)
      • 10.3.9.4. United Kingdom Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 10.3.9.5. United Kingdom Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 10.3.10. France
      • 10.3.10.1. Overview
      • 10.3.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.3.10.3. France Market Size and Forecast, By Disease Type, 2019 - 2032 (US$ Million)
      • 10.3.10.4. France Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 10.3.10.5. France Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 10.3.11. Russia
      • 10.3.11.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.3.11.2. Russia Market Size and Forecast, By Disease Type, 2019 - 2032 (US$ Million)
      • 10.3.11.3. Russia Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 10.3.11.4. Russia Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 10.3.12. Netherlands
      • 10.3.12.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.3.12.2. Netherlands Market Size and Forecast, By Disease Type, 2019 - 2032 (US$ Million)
      • 10.3.12.3. Netherlands Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 10.3.12.4. Netherlands Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 10.3.13. Sweden
      • 10.3.13.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.3.13.2. Sweden Market Size and Forecast, By Disease Type, 2019 - 2032 (US$ Million)
      • 10.3.13.3. Sweden Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 10.3.13.4. Sweden Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 10.3.14. Poland
      • 10.3.14.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.3.14.2. Poland Market Size and Forecast, By Disease Type, 2019 - 2032 (US$ Million)
      • 10.3.14.3. Poland Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 10.3.14.4. Poland Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 10.3.15. Rest of Europe
      • 10.3.15.1. Overview
      • 10.3.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.3.15.3. Rest of the Europe Market Size and Forecast, By Disease Type, 2019 - 2032 (US$ Million)
      • 10.3.15.4. Rest of the Europe Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 10.3.15.5. Rest of the Europe Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
  • 10.4. Asia Pacific (APAC)
    • 10.4.1. Overview
    • 10.4.2. Diabetic Neuropathy Treatment Key Manufacturers in Asia Pacific
    • 10.4.3. Asia Pacific Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 10.4.4. Asia Pacific Market Size and Forecast, By Disease Type, 2019 - 2032 (US$ Million)
    • 10.4.5. Asia Pacific Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
    • 10.4.6. Asia Pacific Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 10.4.7. India
      • 10.4.7.1. Overview
      • 10.4.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.4.7.3. India Market Size and Forecast, By Disease Type, 2019 - 2032 (US$ Million)
      • 10.4.7.4. India Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 10.4.7.5. India Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 10.4.8. China
      • 10.4.8.1. Overview
      • 10.4.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.4.8.3. China Market Size and Forecast, By Disease Type, 2019 - 2032 (US$ Million)
      • 10.4.8.4. China Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 10.4.8.5. China Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 10.4.9. Japan
      • 10.4.9.1. Overview
      • 10.4.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.4.9.3. Japan Market Size and Forecast, By Disease Type, 2019 - 2032 (US$ Million)
      • 10.4.9.4. Japan Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 10.4.9.5. Japan Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 10.4.10. South Korea
      • 10.4.10.1. Overview
      • 10.4.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.4.10.3. South Korea Market Size and Forecast, By Disease Type, 2019 - 2032 (US$ Million)
      • 10.4.10.4. South Korea Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 10.4.10.5. South Korea Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 10.4.11. Australia
      • 10.4.11.1. Overview
      • 10.4.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.4.11.3. Australia Market Size and Forecast, By Disease Type, 2019 - 2032 (US$ Million)
      • 10.4.11.4. Australia Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 10.4.11.5. Australia Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 10.4.12. Thailand
      • 10.4.12.1. Overview
      • 10.4.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.4.12.3. Thailand Market Size and Forecast, By Disease Type, 2019 - 2032 (US$ Million)
      • 10.4.12.4. Thailand Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 10.4.12.5. Thailand Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 10.4.13. Indonesia
      • 10.4.13.1. Overview
      • 10.4.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.4.13.3. Indonesia Market Size and Forecast, By Disease Type, 2019 - 2032 (US$ Million)
      • 10.4.13.4. Indonesia Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 10.4.13.5. Indonesia Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 10.4.14. Philippines
      • 10.4.14.1. Overview
      • 10.4.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.4.14.3. Philippines Market Size and Forecast, By Disease Type, 2019 - 2032 (US$ Million)
      • 10.4.14.4. Philippines Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 10.4.14.5. Philippines Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 10.4.15. Rest of APAC
      • 10.4.15.1. Overview
      • 10.4.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.4.15.3. Rest of APAC Market Size and Forecast, By Disease Type, 2019 - 2032 (US$ Million)
      • 10.4.15.4. Rest of APAC Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 10.4.15.5. Rest of APAC Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
  • 10.5. Latin America
    • 10.5.1. Overview
    • 10.5.2. Diabetic Neuropathy Treatment Key Manufacturers in Latin America
    • 10.5.3. Latin America Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 10.5.4. Latin America Market Size and Forecast, By Disease Type, 2019 - 2032 (US$ Million)
    • 10.5.5. Latin America Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
    • 10.5.6. Latin America Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 10.5.7. Brazil
      • 10.5.7.1. Overview
      • 10.5.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.5.7.3. Brazil Market Size and Forecast, By Disease Type, 2019 - 2032 (US$ Million)
      • 10.5.7.4. Brazil Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 10.5.7.5. Brazil Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 10.5.8. Mexico
      • 10.5.8.1. Overview
      • 10.5.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.5.8.3. Mexico Market Size and Forecast, By Disease Type, 2019 - 2032 (US$ Million)
      • 10.5.8.4. Mexico Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 10.5.8.5. Mexico Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 10.5.9. Argentina
      • 10.5.9.1. Overview
      • 10.5.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.5.9.3. Argentina Market Size and Forecast, By Disease Type, 2019 - 2032 (US$ Million)
      • 10.5.9.4. Argentina Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 10.5.9.5. Argentina Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 10.5.10. Colombia
      • 10.5.10.1. Overview
      • 10.5.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.5.10.3. Colombia Market Size and Forecast, By Disease Type, 2019 - 2032 (US$ Million)
      • 10.5.10.4. Colombia Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 10.5.10.5. Colombia Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 10.5.11. Rest of LATAM
      • 10.5.11.1. Overview
      • 10.5.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.5.11.3. Rest of LATAM Market Size and Forecast, By Disease Type, 2019 - 2032 (US$ Million)
      • 10.5.11.4. Rest of LATAM Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 10.5.11.5. Rest of LATAM Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
  • 10.6. Middle East and Africa
    • 10.6.1. Overview
    • 10.6.2. Diabetic Neuropathy Treatment Key Manufacturers in Middle East and Africa
    • 10.6.3. Middle East and Africa Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 10.6.4. Middle East and Africa Market Size and Forecast, By Disease Type, 2019 - 2032 (US$ Million)
    • 10.6.5. Middle East and Africa Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
    • 10.6.6. Middle East and Africa Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 10.6.7. Saudi Arabia
      • 10.6.7.1. Overview
      • 10.6.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.6.7.3. Saudi Arabia Market Size and Forecast, By Disease Type, 2019 - 2032 (US$ Million)
      • 10.6.7.4. Saudi Arabia Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 10.6.7.5. Saudi Arabia Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 10.6.8. United Arab Emirates
      • 10.6.8.1. Overview
      • 10.6.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.6.8.3. United Arab Emirates Market Size and Forecast, By Disease Type, 2019 - 2032 (US$ Million)
      • 10.6.8.4. United Arab Emirates Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 10.6.8.5. United Arab Emirates Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 10.6.9. Israel
      • 10.6.9.1. Overview
      • 10.6.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.6.9.3. Israel Market Size and Forecast, By Disease Type, 2019 - 2032 (US$ Million)
      • 10.6.9.4. Israel Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 10.6.9.5. Israel Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 10.6.10. Turkey
      • 10.6.10.1. Overview
      • 10.6.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.6.10.3. Turkey Market Size and Forecast, By Disease Type, 2019 - 2032 (US$ Million)
      • 10.6.10.4. Turkey Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 10.6.10.5. Turkey Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 10.6.11. Algeria
      • 10.6.11.1. Overview
      • 10.6.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.6.11.3. Algeria Market Size and Forecast, By Disease Type, 2019 - 2032 (US$ Million)
      • 10.6.11.4. Algeria Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 10.6.11.5. Algeria Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 10.6.12. Egypt
      • 10.6.12.1. Overview
      • 10.6.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.6.12.3. Egypt Market Size and Forecast, By Disease Type, 2019 - 2032 (US$ Million)
      • 10.6.12.4. Egypt Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 10.6.12.5. Egypt Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 10.6.13. Rest of MEA
      • 10.6.13.1. Overview
      • 10.6.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.6.13.3. Rest of MEA Market Size and Forecast, By Disease Type, 2019 - 2032 (US$ Million)
      • 10.6.13.4. Rest of MEA Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 10.6.13.5. Rest of MEA Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)

11. Key Vendor Analysis- Diabetic Neuropathy Treatment Industry

  • 11.1. Competitive Dashboard
  • 11.2. Company Profiles
    • 11.2.1. Pfizer Inc.
    • 11.2.2. Eli Lilly and Company
    • 11.2.3. Astellas Pharma Inc.
    • 11.2.4. GlaxoSmithKline plc.
    • 11.2.5. Boehringer Ingelheim
    • 11.2.6. NeuroMetrix Inc.
    • 11.2.7. Axovant Gene Therapies Ltd.
    • 11.2.8. Eton Pharmaceuticals
    • 11.2.9. Alnylam Pharmaceuticals
    • 11.2.10. Novartis International AG
    • 11.2.11. Sanofi
    • 11.2.12. Johnson & Johnson
    • 11.2.13. Amgen Inc.
    • 11.2.14. AbbVie Inc.
    • 11.2.15. Merck & Co.
    • 11.2.16. Vertex Pharmaceuticals
    • 11.2.17. Others

12. 360 Degree Analyst View

13. Appendix

  • 13.1. Research Methodology
  • 13.2. References
  • 13.3. Abbreviations
  • 13.4. Disclaimer
  • 13.5. Contact Us

List of Tables

  • TABLE List of data sources
  • TABLE Market drivers; Impact Analysis
  • TABLE Market restraints; Impact Analysis
  • TABLE Diabetic Neuropathy Treatment Market: Disease Type Snapshot (2023)
  • TABLE Segment Dashboard; Definition and Scope, by Disease Type
  • TABLE Global Diabetic Neuropathy Treatment Market, by Disease Type 2019-2032 (USD Million)
  • TABLE Diabetic Neuropathy Treatment Market: Drug Class Snapshot (2023)
  • TABLE Segment Dashboard; Definition and Scope, by Drug Class
  • TABLE Global Diabetic Neuropathy Treatment Market, by Drug Class 2019-2032 (USD Million)
  • TABLE Diabetic Neuropathy Treatment Market: Distribution Channel Snapshot (2023)
  • TABLE Segment Dashboard; Definition and Scope, by Distribution Channel
  • TABLE Global Diabetic Neuropathy Treatment Market, by Distribution Channel 2019-2032 (USD Million)
  • TABLE Diabetic Neuropathy Treatment Market: Regional snapshot (2023)
  • TABLE Segment Dashboard; Definition and Scope, by Region
  • TABLE Global Diabetic Neuropathy Treatment Market, by Region 2019-2032 (USD Million)
  • TABLE North America Diabetic Neuropathy Treatment Market, by Country, 2019-2032 (USD Million)
  • TABLE North America Diabetic Neuropathy Treatment Market, by Disease Type, 2019-2032 (USD Million)
  • TABLE North America Diabetic Neuropathy Treatment Market, by Drug Class, 2019-2032 (USD Million)
  • TABLE North America Diabetic Neuropathy Treatment Market, by Distribution Channel, 2019-2032 (USD Million)
  • TABLE Europe Diabetic Neuropathy Treatment Market, by Country, 2019-2032 (USD Million)
  • TABLE Europe Diabetic Neuropathy Treatment Market, by Disease Type, 2019-2032 (USD Million)
  • TABLE Europe Diabetic Neuropathy Treatment Market, by Drug Class, 2019-2032 (USD Million)
  • TABLE Europe Diabetic Neuropathy Treatment Market, by Distribution Channel, 2019-2032 (USD Million)
  • TABLE Asia Pacific Diabetic Neuropathy Treatment Market, by Country, 2019-2032 (USD Million)
  • TABLE Asia Pacific Diabetic Neuropathy Treatment Market, by Disease Type, 2019-2032 (USD Million)
  • TABLE Asia Pacific Diabetic Neuropathy Treatment Market, by Drug Class, 2019-2032 (USD Million)
  • TABLE Asia Pacific Diabetic Neuropathy Treatment Market, by Distribution Channel, 2019-2032 (USD Million)
  • TABLE Latin America Diabetic Neuropathy Treatment Market, by Country, 2019-2032 (USD Million)
  • TABLE Latin America Diabetic Neuropathy Treatment Market, by Disease Type, 2019-2032 (USD Million)
  • TABLE Latin America Diabetic Neuropathy Treatment Market, by Drug Class, 2019-2032 (USD Million)
  • TABLE Latin America Diabetic Neuropathy Treatment Market, by Distribution Channel, 2019-2032 (USD Million)
  • TABLE Middle East and Africa Diabetic Neuropathy Treatment Market, by Country, 2019-2032 (USD Million)
  • TABLE Middle East and Africa Diabetic Neuropathy Treatment Market, by Disease Type, 2019-2032 (USD Million)
  • TABLE Middle East and Africa Diabetic Neuropathy Treatment Market, by Drug Class, 2019-2032 (USD Million)
  • TABLE Middle East and Africa Diabetic Neuropathy Treatment Market, by Distribution Channel, 2019-2032 (USD Million)